Search
Denali Therapeutics Inc
DNLIAdd to Watchlist
25.720USD
-0.170-0.66%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
4.08BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.66%
5 Days
+3.84%
1 Month
+22.24%
6 Months
+55.78%
Year to Date
+55.78%
1 Year
+83.85%
Key Figures
25.960Open
26.355High
1.97MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.24%Turnover Ratio
25.890Prev. Close
25.620Low
38.77MTurnover
LossP/E Static
4.41P/B
0.00%Div Yield TTM
-40.04%ROA
23.77052wk High
0.75Volume Ratio
-422.77MNet Profit
158.66MShares
-2.8803EPS TTM
1.02Beta
-49.59%ROE
12.58052wk Low
2.84%Amplitude
100.00%Gross Margin
4.08BMarket Cap
8.10Reward/Risk
3.32%Risk Rate
TradingKey Stock Score of Denali Therapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Denali Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 60 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.93.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Denali Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Denali Therapeutics Inc Highlights
StrengthsRisks
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -8.93, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 158.73M shares, increasing 0.58% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 61.85K shares of this stock.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
33.933
Target Price
+31.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Denali Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Denali Therapeutics Inc Info
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Ticker SymbolDNLI
CompanyDenali Therapeutics Inc
CEOWatts (Ryan J)
Websitehttps://www.denalitherapeutics.com
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
FAQs
What is the current price of Denali Therapeutics Inc (DNLI)?
The current price of Denali Therapeutics Inc (DNLI) is 25.72.
What is the symbol of Denali Therapeutics Inc?
The ticker symbol of Denali Therapeutics Inc is DNLI.
What is the 52-week high of Denali Therapeutics Inc?
The 52-week high of Denali Therapeutics Inc is 23.77.
What is the 52-week low of Denali Therapeutics Inc?
The 52-week low of Denali Therapeutics Inc is 12.58.
What is the market capitalization of Denali Therapeutics Inc?
The market capitalization of Denali Therapeutics Inc is 4.08B.
Is Denali Therapeutics Inc (DNLI) currently rated as Buy, Hold, or Sell?
According to analysts, Denali Therapeutics Inc (DNLI) has an overall rating of Buy, with a price target of 33.93.
What is the Earnings Per Share (EPS TTM) of Denali Therapeutics Inc (DNLI)?
The Earnings Per Share (EPS TTM) of Denali Therapeutics Inc (DNLI) is -2.97.
